This article was originally published on PharmaTimes http://www.pharmatimes.com/news/ec_extends_license_for_rochechugais_hemlibra_1281593

The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.

Related Posts